Pathophysiology and management of severe hypercalcemia

Area of Science:

• Endocrinology and Bone Metabolism
• Nephrology
• Oncology

Background:

• Severe hypercalcemia, often linked to hyperparathyroidism and malignancy, stems from heightened osteoclastic bone resorption.
• Impaired renal function in hypercalcemia reduces sodium and calcium excretion, while hormones like PTH exacerbate calcium reabsorption.
• While rehydration is an initial step, inhibiting osteoclastic bone resorption is the primary therapeutic goal.

Purpose of the Study:

• To review the pathophysiologic mechanisms of severe hypercalcemia.
• To evaluate various therapeutic agents for inhibiting osteoclastic bone resorption.
• To determine the most effective and safest treatment strategies for hypercalcemia, particularly in patients with malignancy or renal insufficiency.

Main Methods:

• Review of existing literature on hypercalcemia pathophysiology and treatment.
• Comparison of the efficacy and toxicity profiles of calcitonin, plicamycin, gallium nitrate, and bisphosphonates.
• Analysis of treatment selection based on patient factors such as renal function and underlying disease.

Main Results:

• Aminobisphosphonates, like pamidronate, are highly effective in inhibiting osteoclasts, normalizing serum calcium for 1-2 weeks with sustained symptom control.
• Calcitonin acts rapidly but has limited potency and efficacy due to tachyphylaxis.
• Gallium nitrate shows promise but requires optimized administration; plicamycin has cumulative toxicities.
• Aminobisphosphonates are preferred in patients with renal insufficiency due to the nephrotoxicity of gallium and plicamycin.

Conclusions:

• Aminobisphosphonates represent a cornerstone therapy for symptomatic hypercalcemia due to their potency and duration of action.
• Effective management of hypercalcemia involves treating the underlying cause, such as surgery for primary hyperparathyroidism or tumor-specific therapy for malignancy.
• In select advanced malignancy cases, withholding hypercalcemia treatment may be the most compassionate approach. Future therapies aim for safer, outpatient-administered osteoclast-targeted treatments.